The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
This study has been completed.
Sponsor:
Pfizer
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00163085
First received: September 9, 2005
Last updated: September 21, 2006
Last verified: September 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Estimated Study Completion Date: | January 2006 |
| Estimated Primary Completion Date: | No date given |